CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-20 | Patel Samir Rashmikant Director | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-03-20 | Prudo-Chlebosz Raymond Director | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2025-03-20 | Prudo-Chlebosz Raymond Director | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-03-20 | Huh Hoyoung Director | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2025-03-20 | Huh Hoyoung Director | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-03-20 | Patel Sandip I Director | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2025-03-20 | Patel Sandip I Director | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2025-03-20 | Hombeck Torsten CFO | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2025-03-20 | Hombeck Torsten CFO | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2025-03-20 | Gaslightwala Abizer Director | Grant or award · Stock Option (Right to Buy) | +1,100,000 | 1,100,000 | ||
| 2025-03-20 | Gaslightwala Abizer Director | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2025-03-06 | Patel Sandip I Director | Grant or award | +44,642 | $1.12 | $50K | 496,499 |
| 2025-03-06 | Patel Sandip I Director | Grant or award · Series A Warrants (Right to Buy) | +44,642 | $1.12 | $50K | 44,642 |
| 2025-03-06 | Patel Sandip I Director | Grant or award · Series B Warrants (Right to Buy) | +44,642 | $1.12 | $50K | 44,642 |
| 2025-03-06 | Huh Hoyoung Director | Grant or award | +892,857 | $1.12 | $1000K | 4,695,854 |
| 2025-03-06 | Huh Hoyoung Director | Grant or award · Series A Warrants (Right to Buy) | +892,857 | $1.12 | $1000K | 892,857 |
| 2025-03-06 | Huh Hoyoung Director | Grant or award · Series B Warrants (Right to Buy) | +892,857 | $1.12 | $1000K | 892,857 |
| 2025-03-06 | Prudo-Chlebosz Raymond Director | Grant or award | +446,428 | $1.12 | $500K | 2,484,990 |
| 2025-03-06 | Prudo-Chlebosz Raymond Director | Grant or award · Series A Warrants (Right to Buy) | +446,428 | $1.12 | $500K | 446,428 |
| 2025-03-06 | Prudo-Chlebosz Raymond Director | Grant or award · Series B Warrants (Right to Buy) | +446,428 | $1.12 | $500K | 446,428 |
Page 6 of 11 · 216 trades